Big pharma gone bad: A timeline of settlements

Sometimes pharma companies bend the rules. And increasingly, they're getting caught, writes FiercePharma Editor Maureen Martino. After Novartis' recent $422.5 million settlement  with the U.S. Attorney's office and reader requests, FiercePharma looked back at other Department of Justice and government fines levied against Big Pharma for improper marketing and other infractions. Those fines range from a relatively light slap on the wrists to multi-billion dollar charges in addition to criminal penalties. Special Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.